FY2018 EPS Estimates for Allergan plc (AGN) Cut by Analyst

Allergan plc (NYSE:AGN) – Research analysts at Gabelli dropped their FY2018 EPS estimates for shares of Allergan in a research report issued on Wednesday. Gabelli analyst K. Kedra now expects that the company will post earnings per share of $15.95 for the year, down from their prior forecast of $16.20. Gabelli also issued estimates for Allergan’s FY2019 earnings at $16.75 EPS and FY2020 earnings at $18.95 EPS.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter last year, the business posted $3.32 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis.

Several other research firms have also commented on AGN. Cantor Fitzgerald set a $191.00 price target on shares of Allergan and gave the company a “hold” rating in a report on Tuesday, December 12th. Credit Suisse Group set a $243.00 price target on shares of Allergan and gave the company an “outperform” rating in a report on Tuesday, October 17th. Citigroup reduced their price target on shares of Allergan from $280.00 to $240.00 and set a “buy” rating for the company in a report on Thursday, October 19th. Deutsche Bank restated a “buy” rating and issued a $215.00 price target on shares of Allergan in a report on Tuesday. Finally, Wells Fargo & Co restated a “buy” rating on shares of Allergan in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $226.95.

Allergan (NYSE:AGN) traded down $1.00 during trading hours on Friday, hitting $176.12. 2,270,825 shares of the stock traded hands, compared to its average volume of 2,492,762. Allergan has a twelve month low of $160.07 and a twelve month high of $256.80. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The company has a market cap of $58,910.00, a price-to-earnings ratio of -7.80, a P/E/G ratio of 1.18 and a beta of 1.11.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Peloton Wealth Strategists grew its position in Allergan by 37.1% during the 3rd quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock worth $2,149,000 after purchasing an additional 2,835 shares during the last quarter. Sumitomo Life Insurance Co. grew its position in Allergan by 39.0% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after purchasing an additional 4,244 shares during the last quarter. Colony Group LLC grew its position in Allergan by 9.9% during the 2nd quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after purchasing an additional 3,577 shares during the last quarter. Clear Harbor Asset Management LLC grew its position in Allergan by 67.7% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 5,039 shares of the company’s stock worth $1,033,000 after purchasing an additional 2,035 shares during the last quarter. Finally, Alta Capital Management LLC grew its position in Allergan by 1.4% during the 3rd quarter. Alta Capital Management LLC now owns 161,377 shares of the company’s stock worth $33,074,000 after purchasing an additional 2,151 shares during the last quarter. Hedge funds and other institutional investors own 81.14% of the company’s stock.

In related news, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of Allergan stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is currently owned by company insiders.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, November 17th were paid a dividend of $0.70 per share. The ex-dividend date was Thursday, November 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.59%. Allergan’s dividend payout ratio (DPR) is presently -12.39%.

Allergan announced that its board has authorized a stock repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 2.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: “FY2018 EPS Estimates for Allergan plc (AGN) Cut by Analyst” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.thestockobserver.com/2018/01/12/fy2018-eps-estimates-for-allergan-plc-agn-cut-by-analyst.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply